The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant
immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain
metastases. The primary objectives of this study are to 1) assess the feasibility of
neoadjuvant ipilimumab and nivolumab treatment before surgery and stereotactic radiosurgery
(SRS) in patients with solid tumor brain metastases as measured by the proportion of patients
who have their surgery delayed or surgery never occurs, and 2) demonstrate that neoadjuvant
immunotherapy will increase proliferation of circulating T-cells compared to baseline
measurements. Exploratory objectives include describing patient progression free survival and
overall survival, time to local and distant intracranial progression, and the rate of
radiation necrosis. The rate of radionecrosis will also be explored, as immune expression
profiles.